DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Durvalumab Plus Tremelimumab
Drug: HAIC (GEMOX)

First Posted Date: 2025-04-01

Last Posted Date: 2025-04-01

Lead Sponsor: UNICANCER

Target Recruit Count: 196

Registration Number: NCT06904170

Locations: 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷
AP-HP Hôpital Beaujon, Clichy, France
🇫🇷
CHU Hôtel-Dieu, Nantes, France

and more 7 locations

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Metastatic Esophageal Adenocarcinoma
Advanced Esophageal Adenocarcinoma
Metastatic Gastric Adenocarcinoma
Advanced Gastric Adenocarcinoma

Interventions: Drug: Ivonescimab
Drug: FOLFOX regimen
Drug: Irinotecan
Drug: Paclitaxel

First Posted Date: 2025-02-26

Last Posted Date: 2025-02-26

Lead Sponsor: UNICANCER

Target Recruit Count: 88

Registration Number: NCT06846346

Locations: 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
Institut de Cancerologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Phase 2

Not yet recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Stage IV

Interventions: Drug: trastuzumab derxutecan

First Posted Date: 2024-11-08

Last Posted Date: 2025-01-15

Lead Sponsor: UNICANCER

Target Recruit Count: 80

Registration Number: NCT06680596

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells

Phase 2

Recruiting

Conditions: Solid Tumor, Miscellaneous

Interventions: Drug: Pemigatinib

First Posted Date: 2024-10-22

Last Posted Date: 2025-05-13

Lead Sponsor: UNICANCER

Target Recruit Count: 40

Registration Number: NCT06653777

Locations: 🇫🇷
CHU de BREST, Brest, France
🇫🇷
Institut Curie, Paris, France
🇫🇷
CHU Poitiers, Poitiers, France

and more 2 locations

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

Phase 3

Not yet recruiting

Conditions: High Risk Prostate Carcinoma
Prostate Cancer

Interventions: Drug: ADT (Standard of Care)
Drug: Darolutamide
Radiation: Stereotactic Body RadioTherapy (SBRT)
Radiation: radiotherapy

First Posted Date: 2024-10-03

Last Posted Date: 2025-03-11

Lead Sponsor: UNICANCER

Target Recruit Count: 700

Registration Number: NCT06625970

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Phase 3

Not yet recruiting

Conditions: Breast Cancers
Triple Negative Breast Cancer (TNBC)

Interventions: Other: Deescalation
Drug: Pembrolizumab

First Posted Date: 2024-09-23

Last Posted Date: 2025-02-21

Lead Sponsor: UNICANCER

Target Recruit Count: 2454

Registration Number: NCT06606730

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Phase 2

Not yet recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: FOLFOX regimen
Drug: Ivonescimab

First Posted Date: 2024-07-31

Last Posted Date: 2025-04-25

Lead Sponsor: UNICANCER

Target Recruit Count: 72

Registration Number: NCT06529718

Locations: 🇫🇷
Institute Mutualiste Montsouris, Paris, France
🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
🇬🇧
University College London, London, United Kingdom

and more 1 locations

Blood Biomarkers Based Screening for HPV-driven OPC

Not Applicable

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Human Papilloma Virus
Anal Cancer

Interventions: Diagnostic Test: HPV16-E6 serology and HPV ctDNA

First Posted Date: 2024-07-30

Last Posted Date: 2024-07-30

Lead Sponsor: UNICANCER

Target Recruit Count: 10000

Registration Number: NCT06528353

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Phase 2

Recruiting

Conditions: Leiomyosarcoma Uterus

Interventions: Drug: Doxorubicin
Drug: Trabectedin

First Posted Date: 2024-07-29

Last Posted Date: 2025-03-30

Lead Sponsor: UNICANCER

Target Recruit Count: 198

Registration Number: NCT06524583

Locations: 🇫🇷
Centre Léon Berard, Lyon, France
🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
La Timone University Hospital, Marseille, France

and more 22 locations

Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Not Applicable

Recruiting

Conditions: Metastatic Triple-Negative Breast Carcinoma

Interventions: Device: Cureety techcare

First Posted Date: 2024-07-17

Last Posted Date: 2024-07-26

Lead Sponsor: UNICANCER

Target Recruit Count: 472

Registration Number: NCT06505018

Locations: 🇫🇷
Groupe Hospitalier de La Rochelle-Ré-Aunis, La Rochelle, France
🇫🇷
Institut de Cancérologie des Hauts-de-France (ICHF), Arras, France
🇫🇷
CH Aunay-Bayeux, Bayeux, France

and more 48 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy